Using human genetics to discover new therapeutic targets for plasma lipids

Area of Science:

• Genetics
• Cardiovascular Disease Research
• Pharmacogenomics

Background:

• Genetic variations, including mutations, influence disease risk and presentation.
• Familial hypercholesterolaemia is often caused by rare mutations, while common alleles typically have minor effects.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) mutations are an exception, being common with substantial phenotypic impact.

Purpose of the Study:

• To highlight the unusual nature of PCSK9 mutations as common variants with large effects.
• To underscore the translation of genetic discoveries into clinical therapeutics, exemplified by PCSK9 inhibitors.
• To discuss the evolution of genetic discovery methods from linkage analysis to whole-exome sequencing.

Main Methods:

• Review of genetic variation principles and selection pressures.
• Analysis of PCSK9 mutations in African Americans and their association with coronary heart disease (CHD) risk.
• Comparison of traditional genetic analysis (linkage, GWAS) with whole-exome sequencing (WES).

Main Results:

• Loss-of-function PCSK9 mutations are prevalent in African Americans (~2.5%) and significantly reduce CHD risk.
• PCSK9 inhibitors represent a successful therapeutic strategy derived from genetic insights.
• WES has identified novel gene mutations (e.g., ANGPTL3, APOC3) linked to lipid disorders and CHD protection.

Conclusions:

• PCSK9 mutations exemplify how common genetic variants can have profound clinical effects.
• Whole-exome sequencing is a powerful tool for discovering genetic mutations underlying complex diseases.
• Genetic insights are crucial for advancing personalized medicine and developing targeted therapies.